Law360 (July 17, 2020, 4:21 PM EDT) -- Amicus Therapeutics, a biotechnology company in commercial and developmental stages for its various planned treatments for genetic disorders, said Friday it had raised $400 million in credit financing from a British investment group.
Cranbury, New Jersey-based Amicus Therapeutics Inc. said in the statement that it had entered a $400 million credit facility with London-based Hayfin Capital Management and that it will use the proceeds for corporate purposes to refinance existing debt and product development.
"Today's agreement with Hayfin has provided us a path to attain profitability without the need to access the equity markets," John Crowley, Amicus chairman and CEO, said...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!